Operating CF
$21.22B
Capex
−$359.00M
Free Cash Flow
$20.86B
FCF Margin
+98.3%
Cash flow waterfall for AbbVie (ABBV) — TTM through Q1 2026
Free cash flow: $20.86B
Note: Other Investing is large — driven mainly by purchases or sales of investments.
Cash flow breakdown for AbbVie (ABBV) — TTM through Q1 2026
| Line item | Amount | Running total |
|---|---|---|
| Operating Cash Flow | $21.22B | $21.22B |
| Capital Expenditure | −$359.00M | $20.86B |
| Free Cash Flow | $20.86B | $20.86B |
| Acquisitions | $334.00M | $21.20B |
| Other Investing | −$6.46B | $14.74B |
| Share Buybacks | −$1.50B | $13.24B |
| Dividends Paid | −$11.82B | $1.42B |
| Net Debt Change | $2.63B | $4.05B |
| Other Financing & FX | $165.00M | $4.22B |
| Net Cash Increase | $4.22B | $4.22B |
- Operating Cash Flow$21.22B
- Capital Expenditure−$359.00M
- Free Cash Flow$20.86B
- Acquisitions$334.00M
- Other Investing−$6.46B
- Share Buybacks−$1.50B
- Dividends Paid−$11.82B
- Net Debt Change$2.63B
- Other Financing & FX$165.00M
- Net Cash Increase$4.22B
Want to see what drove the FCF change?Free Cash Flow Bridge
Frequently asked questions
Data & methodology
AbbVie (ABBV) Key Financials
Charts, filings, and peer comparison for every metric
Income Statement
Balance Sheet
Cash Flow
Explore more
Deep-dives across the income statement, cash flow, capital return, and valuation
Overview
Income Statement